Kidney Week

Abstract: PUB375

Impact of SARS-CoV-2 Vaccination and/or COVID-19 in the Clinical Course of Patients with IgA Nephropathy

Session Information

• Publication Only

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Lionaki, Sophia, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece

Sophia Lionaki, MD, PhD

• Sardeli, Angeliki, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece

Angeliki Sardeli, MD

• Marinaki, Smaragdi, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Greece

Smaragdi Marinaki, MD

• Gkalitsiou, Dimitra, Geniko Nosokomeio Athenon Giorgos Gennematas, Athens, Attike, Greece

Dimitra Gkalitsiou, DrMed

• Pelagia, Kriki, Demokriteio Panepistemio Thrakes, Komotini, East Macedonia and Thrace, Greece

Kriki Pelagia

• Karagiannis, Minas, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece

Minas Karagiannis, MD

• Kantartzi, Konstantia, Demokriteio Panepistemio Thrakes, Komotini, East Macedonia and Thrace, Greece

Konstantia Kantartzi

• Moustakas, Georgios, Geniko Nosokomeio Athenon Giorgos Gennematas, Athens, Attike, Greece

Georgios Moustakas, MD, PhD

• Papasotiriou, Marios, Panepistemio Patron, Patra, Periféria Dhitikís Elládh, Greece

Marios Papasotiriou, MD, PhD

• Grapsa, Eirini, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Attica, Greece

Eirini Grapsa, PhD

• Panagoutsos, Stylianos A., Demokriteio Panepistemio Thrakes, Komotini, East Macedonia and Thrace, Greece

Stylianos A. Panagoutsos, MD

Background

To explore the impact, if any, of SARS-CoV-2 vaccination and/or COVID-19 in the disease course of patients with IgA nephropathy (IgAN).

Methods

This is a multicenter, retrospective study of patients with biopsy-proven IgAN, who were vaccinated against SARS-CoV-2 or were infected or both. Patients with ESKD prior to vaccination or infection were excluded. Adverse effects of vaccination, doses administered, immunosuppressive therapy and outcome of glomerular disease, clinical picture of infection, need for hospitalization and outcome of infection were recorded.

Results

Included patients (N=51) with IgAN were 46.5(±16.58) years old and 30 (58.8%) were males. The time interval from IgAN diagnosis was 80.27 (±71.5) and 41(80.4%) were vaccinated within 65.9 (±77.7) months from the diagnostic kidney biopsy with 3 (±0.75) doses while 19.8% of patients were on immunosuppressive therapy at the time of vaccination. 14.6% of patients reported systemic and 26.8% local side effects from vaccination. In total, 37(72.5%) patients were infected of whom 72.9% had been vaccinated. 85.3% of patients had symptoms at the time of testing for SARS-CoV-2. One patient was hospitalized and all had complete recovery. One patient (2.7%) experienced recurrence of IgAN within 3.5 months after infection.

Conclusion

In this study, SARS-CoV-2 vaccination was shown safe for patients with IgAN while it was associated with an uncomplicated outcome of the related infection.